Cellectis (CLLS) FCF Margin (2015 - 2026)
Cellectis (CLLS) recorded quarterly FCF Margin of 262.16% in Q1 2026, down 172.33% quarter-over-quarter from 96.26% in Q4 2025, and down 10482.0% on a YoY basis from N/an in Q1 2025.
Cellectis (CLLS) FCF Margin (2015 - 2026) Analysis & Trends
Cellectis' FCF Margin history runs 12 years deep, the most recent figure standing at 262.16% for Q1 2026.
- In Q1 2026, FCF Margin fell 10482.0% year-over-year to 262.16%; the TTM figure through Mar 2026 stood at 53.67% (down 10199.0% YoY), while the FY2025 annual figure was 54.01%, down 9547.0% from the prior year.
- FCF Margin was 262.16% for Q1 2026 at Cellectis, down from 96.26% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 15039.93% in Q4 2023 to a low of 20225.18% in Q1 2023.
- Historically, FCF Margin has averaged 2681.99% across 5 years, with a median of 157.34% in 2025.
- The sharpest annual moves came in 2023 and 2024: FCF Margin sank 1806386 bps in 2023, then soared 1971509 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 35.2% in 2022, then soared by 42830 bps to 15039.93% in 2023, then slumped by 100 bps to 22.83% in 2024, then sank by 322 bps to 96.26% in 2025, then slumped by 172 bps to 262.16% in 2026.
- The last three FCF Margin figures came in at 262.16% (Q1 2026), 96.26% (Q4 2025), and 1.11% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -262.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -262.16% |
| Dec 31, 2025 | -96.26% |
| Sep 30, 2025 | -1.11% |
| Jun 30, 2025 | -59.82% |
| Mar 31, 2025 | -157.34% |
| Dec 31, 2024 | -22.83% |
| Sep 30, 2024 | -31.19% |
| Jun 30, 2024 | 660.19% |
| Mar 31, 2024 | -510.09% |
| Dec 31, 2023 | 15,039.93% |
| Sep 30, 2023 | -10,825.81% |
| Jun 30, 2023 | -10,546.63% |
| Mar 31, 2023 | -20,225.18% |
| Dec 31, 2022 | -35.20% |
| Sep 30, 2022 | -14,625.71% |
| Jun 30, 2022 | -1,733.28% |
| Mar 31, 2022 | -2,161.32% |
| Dec 31, 2021 | -564.01% |
| Sep 30, 2021 | -310.55% |
| Jun 30, 2021 | -59.73% |